Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability | VuMedi

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability

By ESMO 2022 Conference Coverage FEATURING Julien Taieb

By ESMO 2022 Conference Coverage FEATURING Julien Taieb

15 views

September 15, 2022

Comments 0

Login to view comments. Click here to Login